China Accepts Review of Innovent Sintilimab Combination for Advanced Melanoma
China has accepted for review a combination of Innovent’s sintilimab and GC101 for advanced melanoma.
China has accepted for review a combination of Innovent’s sintilimab and GC101 for advanced melanoma.